
AstraZeneca breast cancer medicine slows disease by over six months
New York: AstraZeneca Plc's experimental breast cancer pill delayed disease progression by over six months, according to data from a new study that is likely to capture investors' attention. Camizestrant, in combination with other cancer medicines, …